Revvity (NYSE:RVTY) Upgraded at Cfra

Key Points

• Cfra upgraded Revvity from “hold” to “buy,” adding to mixed analyst views; MarketBeat’s consensus rating remains “hold,” with an average price target of $124.43.
• Revvity beat quarterly estimates, reporting EPS of $1.38 versus $1.30 expected and revenue of $728.9 million versus $694.7 million expected. Revenue rose 4.3% year over year.
• Shares opened at $163.55, near the 52-week high of $171.74, while the stock’s P/E ratio stood at 77.88.

Revvity (NYSE:RVTY - Get Free Report) was upgraded by Cfra from a "hold" rating to a "buy" rating in a research note issued on Wednesday, MarketBeat Ratings reports.

A number of other equities research analysts have also recently commented on RVTY. William Blair initiated coverage on shares of Revvity in a research report on Monday, October 5th. They set an "outperform" rating for the company. Weiss Ratings upgraded Revvity from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, October 8th. Zacks Research upgraded Revvity from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 4th. KeyCorp upped their target price on Revvity from $125.00 to $165.00 and gave the company an "overweight" rating in a research report on Friday, September 4th. Finally, Wall Street Zen cut Revvity from a "buy" rating to a "hold" rating in a research note on Sunday, August 16th. Six equities research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat.com, Revvity currently has a consensus rating of "Hold" and an average target price of $124.43.

Revvity Price Performance

Shares of RVTY stock opened at $163.55 on Wednesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. The company has a market capitalization of $18.25 billion, a P/E ratio of 77.88, a P/E/G ratio of 2.76 and a beta of 1.08. The company's 50-day simple moving average is $145.89 and its two-hundred day simple moving average is $112.62. Revvity has a one year low of $81.22 and a one year high of $171.74.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.08. The firm had revenue of $728.90 million during the quarter, compared to the consensus estimate of $694.73 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company's revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.18 earnings per share. As a group, equities analysts anticipate that Revvity will post 5.36 EPS for the current year.

Insiders Place Their Bets

In other news, insider Maxwell Krakowiak sold 1,631 shares of the firm's stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the completion of the transaction, the insider directly owned 14,781 shares in the company, valued at $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Tajinder S. Vohra sold 7,330 shares of the firm's stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total value of $1,032,650.40. Following the completion of the transaction, the insider owned 6,635 shares of the company's stock, valued at approximately $934,738.80. The trade was a 52.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 9,045 shares of company stock worth $1,281,439 over the last three months. Corporate insiders own 0.85% of the company's stock.

Hedge Funds Weigh In On Revvity

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Pillar Financial Advisors LLC acquired a new position in shares of Revvity in the 3rd quarter valued at $29,000. Heritage Family Offices LLP purchased a new stake in Revvity during the third quarter worth $37,000. Ascentis Independent Advisors purchased a new stake in Revvity during the first quarter worth $29,000. Root Financial Partners LLC acquired a new stake in Revvity during the third quarter valued at $64,000. Finally, Global Retirement Partners LLC acquired a new stake in Revvity during the second quarter valued at $51,000. Institutional investors and hedge funds own 86.65% of the company's stock.

Revvity News Summary

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported adjusted EPS of $1.38, above analyst estimates of about $1.30, and revenue of $728.9 million versus forecasts of about $694.7 million. Revenue rose 4.3% year over year, while EPS increased from $1.18 a year earlier. Article: Revvity Edges Past Q3 2026 Estimates
• Positive Sentiment: The company raised its 2026 outlook after the quarterly beat. Reports point to Life Sciences growth, margin expansion, AI-related demand and operational execution as contributors to broad-based growth—supporting the case for continued earnings momentum. Article: Q3 Earnings Beat on Life Sciences Strength Article: AI Demand and Operational Execution
• Neutral Sentiment: Revvity reaffirmed its dividend, providing continuity for income-focused shareholders, but the announcement alone does not materially change the growth outlook. Article: Revvity Reaffirms Its Dividend
• Negative Sentiment: Valuation is a key counterweight: one report questions whether the stock is now too expensive. The provided background also shows a high P/E ratio and a share price near its 52-week high, which could leave less room for gains if growth or guidance disappoints. Article: Earnings Beat Might Change the Case for Revvity

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.